251 related articles for article (PubMed ID: 10871727)
1. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
[TBL] [Abstract][Full Text] [Related]
2. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
[TBL] [Abstract][Full Text] [Related]
3. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
Holmberg LA; Sandmaier BM
Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
[TBL] [Abstract][Full Text] [Related]
5. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
Holmberg LA; Demirer T; Rowley S; Buckner CD; Goodman G; Maziarz R; Klarnet J; Zuckerman N; Harrer G; McCloskey R; Gersh R; Goldberg R; Nichols W; Jacobs A; Weiden P; Montgomery P; Rivkin S; Appelbaum FR; Bensinger WI
Bone Marrow Transplant; 1998 Oct; 22(7):651-9. PubMed ID: 9818692
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Schiffman KS; Bensinger WI; Appelbaum FR; Rowley S; Lilleby K; Clift RA; Weaver CH; Demirer T; Sanders JE; Petersdorf S; Gooley T; Weiden P; Zuckerman N; Montgomery P; Maziarz R; Klarnet JP; Rivkin S; Trueblood K; Storb R; Holmberg L; Buckner CD
Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
[TBL] [Abstract][Full Text] [Related]
7. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
8. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H
Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
[TBL] [Abstract][Full Text] [Related]
9. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma].
Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W
Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276
[TBL] [Abstract][Full Text] [Related]
10. Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
Sportès C; McCarthy NJ; Hakim F; Steinberg SM; Liewehr DJ; Weng D; Kummar S; Gea-Banacloche J; Chow CK; Dean RM; Castro KM; Marchigiani D; Bishop MR; Fowler DH; Gress RE
Biol Blood Marrow Transplant; 2005 Jun; 11(6):472-83. PubMed ID: 15931636
[TBL] [Abstract][Full Text] [Related]
11. Theratope vaccine (STn-KLH).
Holmberg LA; Sandmaier BM
Expert Opin Biol Ther; 2001 Sep; 1(5):881-91. PubMed ID: 11728222
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
[TBL] [Abstract][Full Text] [Related]
13. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO
Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999
[TBL] [Abstract][Full Text] [Related]
14. [Tandem transplantation with peripheral autologous hematopoietic blood stem cells in treatment of oncologic and hematologic malignancies. Initial results of the Donauspital, Vienna].
Ruckser R; Kier P; Sebesta C; Kittl E; Kurz M; Selleny S; Höniger S; Scherz M; Habertheuer KH; Zelenka P
Wien Med Wochenschr; 1995; 145(2-3):41-4, 46-7. PubMed ID: 7762251
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
[TBL] [Abstract][Full Text] [Related]
16. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
[TBL] [Abstract][Full Text] [Related]
18. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: Theratope, Biomira Inc.
Morse MA
Curr Opin Mol Ther; 2000 Aug; 2(4):453-8. PubMed ID: 11249777
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
MacLean GD; Miles DW; Rubens RD; Reddish MA; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):309-16. PubMed ID: 8877724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
